Pelthos Therapeutics Inc.
- PTHS · NYSE
- Biological Products, (No Diagnostic Substances)
- Durham, NC
- 92 employees
- CIK 0001919246
Updated from SEC filings through
Top things to know
Executives
-
Scott M. Plesha CEO and President 4/A, 2026-04-01 - Scott Plesha Chief Executive Officer and President 10-K, 2026-03-19
- Knuettel Francis II CFO, Treas & Secty 4, 2026-05-26
-
John M. Gay Chief Financial Officer 3, 2026-04-20 - Francis Knuettel II Chief Financial Officer 10-K, 2026-03-19
-
Sai Rangarao Chief Commercial Officer 4/A, 2026-04-01
Pelthos Therapeutics Inc. is a U.S. public company in biological products, (no diagnostic substances) (SIC 2836), headquartered in Durham, NC. It trades as PTHS on NYSE. Revenue was $16.8M in the fiscal year ending December 31, 2025. It reported about 92 employees. Scott M. Plesha is CEO and President.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $16.8M 10-K, 2026-03-19 | $0 10-K, 2026-03-19 | Not on file | Not on file |
| Operating income | -$32.4M 10-K, 2026-03-19 | -$7.6M 10-K, 2026-03-19 | -$6.9M 10-K, 2025-03-27 | -$2.3M 10-K, 2024-04-16 |
| SG&A | $42.5M 10-K, 2026-03-19 | $6.4M 10-K, 2026-03-19 | $2.7M 10-K, 2025-03-27 | $1.1M 10-K, 2024-04-16 |
| Net income | -$43.3M 10-K, 2026-03-19 | -$8.0M 10-K, 2026-03-19 | -$7.4M 10-K, 2025-03-27 | -$2.5M 10-K, 2024-04-16 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Scott M. Plesha Chief Executive Officer | CEO and President | 4/A, 2026-04-01 |
| Scott Plesha | Chief Executive Officer and President | 10-K, 2026-03-19 |
| Knuettel Francis II | CFO, Treas & Secty | 4, 2026-05-26 |
| John M. Gay | Chief Financial Officer | 3, 2026-04-20 |
| Francis Knuettel II | Chief Financial Officer | 10-K, 2026-03-19 |
| Sai Rangarao Chief Commercial Officer, Pelthos Therapeutics | Chief Commercial Officer | 4/A, 2026-04-01 |
| Peter Greenleaf | Director (Chairman of the Board) | 10-K, 2026-03-19 |
| Andrew Einhorn | Director | 10-K, 2026-03-19 |
| Ezra Friedberg | Director | 10-K, 2026-03-19 |
| Matthew Pauls | Director | 10-K, 2026-03-19 |
| Richard Baxter | Director | 10-K, 2026-03-19 |
| Todd Davis | Director | 10-K, 2026-03-19 |
What Pelthos Therapeutics Inc. does
Pelthos Therapeutics Inc. (the “Company”) is a bio-pharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens.S. Food and Drug Administration (“FDA”) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMI TM , XEPI ® , and XEGLYZE ® .
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 3.8 million (as of August 10, 2026) | 10-Q/A, August 13, 2026 |
|---|---|---|
| Public float | $6.7M (as of June 30, 2025) | 10-K, March 19, 2026 |
| Reportable segments | 2 (period ending June 30, 2026) | 10-Q, August 13, 2026 |
| Latest proxy statement | Meeting September 29, 2026 (filed August 18, 2026) | DEF 14A, August 18, 2026 |
| Auditor | CBIZ CPAs P.C. (Hartford, Connecticut) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| October 2, 2026 | Peter Greenleaf Director | Sale | 797 | $17K | Form 4, October 6, 2026 |
| October 2, 2026 | Ezra M. Friedberg Director | Sale | 558 | $12K | Form 4, October 6, 2026 |
| October 2, 2026 | Matthew Pauls Director | Sale | 786 | $17K | Form 4, October 6, 2026 |
| July 2, 2026 | Ezra M. Friedberg Director | Sale | 558 | $15K | Form 4, July 7, 2026 |
| July 2, 2026 | Matthew Pauls Director | Sale | 786 | $21K | Form 4, July 7, 2026 |
| July 2, 2026 | Peter Greenleaf Director | Sale | 797 | $21K | Form 4, July 7, 2026 |
| June 15, 2026 | Ezra M. Friedberg Director | Sale | 283 | $8K | Form 4, June 17, 2026 |
| June 11, 2026 | Todd C. Davis Director | Buy | 35,948 | $1000K | Form 4, June 15, 2026 |
Recent 8-K events
- 8-K filed 2026-10-30
- Item 1.01 Entry into a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- Item 3.02 Unregistered sales of equity securities
- Item 3.03 Material modification to rights of security holders
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
- Item 5.07 Submission of matters to a vote of security holders
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-10-01
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-08-13
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-13
- Item 4.02 Non-reliance on previously issued financial statements
- 8-K filed 2026-05-28
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-05-21
- Item 4.01 Changes in registrant's certifying accountant
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-05-14
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-04-14
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-04-10
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-03-19
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
Frequently asked questions about Pelthos Therapeutics Inc.
- What does Pelthos Therapeutics Inc. do?
- In its own words, from Item 1 of its 10-K: "Pelthos Therapeutics Inc. (the “Company”) is a bio-pharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens.S. Food and Drug Administration (“FDA”) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMI TM , XEPI ® , and XEGLYZE ® ."
- What is Pelthos Therapeutics Inc.'s revenue?
- $16.8M for the fiscal year ending December 31, 2025, from its 10-K filed March 19, 2026.
- Is Pelthos Therapeutics Inc. profitable?
- Pelthos Therapeutics Inc. reported net income of -$43.3M for the fiscal year ending December 31, 2025.
- How many employees does Pelthos Therapeutics Inc. have?
- About 92 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Pelthos Therapeutics Inc.?
- Scott M. Plesha, CEO and President, as named in a 4/A filed April 1, 2026.
- Who is the CFO of Pelthos Therapeutics Inc.?
- Knuettel Francis II, CFO, Treas & Secty, as named in a 4 filed May 26, 2026.
- Where is Pelthos Therapeutics Inc. headquartered?
- Durham, NC.
- What is Pelthos Therapeutics Inc.'s stock ticker?
- PTHS on NYSE.
- What industry is Pelthos Therapeutics Inc. in?
- Biological Products, (No Diagnostic Substances), SIC code 2836.
- What is Pelthos Therapeutics Inc.'s website?
- pelthos.com. Investor relations: https://ir.pelthos.com.
- When does Pelthos Therapeutics Inc. report earnings next?
- November 12, 2026 at 08:30. Source: ir_events.
- Is Pelthos Therapeutics Inc. a public company?
- Yes. Pelthos Therapeutics Inc. files with the SEC under CIK 0001919246 and trades as PTHS.
- Who audits Pelthos Therapeutics Inc.?
- CBIZ CPAs P.C., Hartford, Connecticut, as named in its latest annual report (10-K).
- How many shares of Pelthos Therapeutics Inc. are outstanding?
- 3.8 million shares as of August 10, 2026, from its 10-Q/A filed August 13, 2026.
- What is Pelthos Therapeutics Inc.'s public float?
- $6.7M as of June 30, 2025, as reported on the cover of its 10-K filed March 19, 2026.
- How many business segments does Pelthos Therapeutics Inc. report?
- 2 reportable segments for the period ending June 30, 2026, from its 10-Q filed August 13, 2026.
- When is Pelthos Therapeutics Inc.'s annual shareholder meeting?
- September 29, 2026, per its proxy statement (DEF 14A) filed August 18, 2026.
- Have Pelthos Therapeutics Inc. insiders traded stock recently?
- Since November 25, 2025, officers and directors reported 13 open-market sales worth about $486K and 1 purchase worth about $1000K on Forms 4 and 5. The most recent: Peter Greenleaf (Director) sold 797 shares on October 2, 2026.